Buaya, Stephanie Jane A.
HRN: 05-24-32 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/04/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/04/2023
09/12/2023
IV
500mg
Q8
Cholelithiasis Cholecystitis
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes